Alcon Inc. (ALC): what the price requires
At today's price, Alcon Inc. (ALC) is priced for today's economics sustained for ~5.4 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/ALC
Headline
| Field | Value |
|---|---|
| Ticker | ALC |
| Company | Alcon Inc. |
| Current price | $68.93/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 9.9% |
| Operating margin today | 10.6% |
| Margin compression implied | -0.7pp |
| Must persist for | 5.4y |
| Multiple paid | 35x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 8.3% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2 years.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | -0.04σ |
| sustained it ~5.4 years at this level | 28% |
| implied end-window share | 0% |
Valuation X-Ray
Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 7.27x | 5 | expensive |
| Earnings | 2.87x | 4 | expensive |
| Relative | 2.94x | 5 | expensive |
| Growth | 0.96x | 3 | justifies |
Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.
Per-Model Detail (n=17)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $87.24 | 0.79x | yes | FCF base $1.8B, growth 5% (input: historical growth), terminal g 4.0%, WACC 7.9%, 6yr projection |
| DCF Exit Multiple | Growth | $71.92 | 0.96x | yes | Exit EV/EBITDA: 35.8x / 37.8x / 39.8x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $42.19 | 1.63x | yes | P/E 31.1x (blended: static sector reference 24x + trailing (TTM) 48x), scenarios: 26.0x / 31.1x / 36.2x (bear / base = reference held flat / bull), EV/EBITDA 22.53x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $15.63 | 4.41x | yes | BV/sh $44.50, ROE (TTM) 3.2%, ke 9.3% |
| Two-Stage Excess Return | Asset | $9.48 | 7.27x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $53.15 | 1.30x | yes | Rev $9.7B, growth 5% (input: historical growth; tapered), Terminal P/S: 2.9x / 3.5x / 4.1x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $17.40 | 3.96x | yes | EPS $1.45, growth 6% (input: historical EPS growth), PEG=8.49 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $24.06 | 2.86x | yes | Normalized EBIT (4y avg op income, one-time charges added back) $1.50B × (1−12%) / WACC 7.9% → EPV (no growth) |
| Residual Income | Asset | $7.09 | 9.72x | yes | BV $44.50 + 5yr PV of (ROE (TTM) 3.2% − Kₑ 9.3%) × BV; BV grows 2.1%/yr |
| Graham Number | Asset | $38.10 | 1.81x | yes | √(22.5 × EPS $1.45 × BVPS $44.50) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $23.46 | 2.94x | yes | EBITDA $1.03B × sector EV/EBITDA 16.0x |
| FCF Yield | Earnings | $27.74 | 2.48x | yes | FCF $1728.0M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | $23.98 | 2.87x | yes | EPS $1.45 × (8.5 + 2×5.6%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $4.57 | 15.08x | yes | BV $44.50 × (ROIC 0.8% / WACC 7.9%) |
| P/Sales Sector | Relative | $78.60 | 0.88x | yes | Revenue $9.73B × sector P/S 4.0x |
| PEG Fair Value | Relative | $12.21 | 5.64x | yes | EPS $1.45 × (PEG 1.5 × growth 5.6% (input: historical EPS growth)) → PE 8.4x |
| Earnings Yield | Earnings | $15.68 | 4.40x | yes | EPS $1.45 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $2.6b |
| Net debt / NOPAT (after-tax) | 2.88x |
| Net debt / operating income (pre-tax) | 2.55x |
| Interest coverage | 5.8x |
| Share count CAGR (dilution) | 0.3% |
| Burning cash | no |
Bullet Takeaways
At $64.67 the market is paying about 33 times operating income, embedding growth held near the self-funding ceiling for roughly five years. The asset, earnings-power and peer methods land well below, so only the forward-growth frame reaches the price.
The product cycle is real: first-quarter 2026 sales rose 6 percent to $2.7 billion, with surgical equipment up 23 percent on the UNITY platform and full-year guidance for 10 to 13 percent earnings-per-share growth.
The business sells elective and reimbursed eye-care products, so it carries regulatory, reimbursement and tariff exposure, and the price leaves little room if any of those headwinds slows the launch momentum.
Bull Case
Start with what the market is pricing in, then weigh it against what Alcon actually is. At $64.67 (June 27, 2026) the price embeds operating growth held near the self-funding ceiling for about five years, a demanding assumption that the asset, earnings-power and peer-multiple frames do not support. What the static frames undervalue is the position: Alcon is the global leader in eye care, spanning a surgical franchise of cataract and refractive equipment, intraocular lenses and consumables, and a vision-care franchise of contact lenses and ocular health products. That is a business with durable demand drivers, an aging population, rising cataract volumes, and growing contact-lens adoption, and high switching costs once a surgeon's operating room is built around Alcon's equipment and lenses.
The current product cycle is converting that position into growth. First-quarter 2026 sales rose 6 percent to $2.7 billion, with the surgical franchise up 6 percent to $1.5 billion and, within it, equipment sales up 23 percent to $253 million on strong momentum from the new UNITY surgical platform. Vision care grew 6 percent to $1.2 billion, with contact lenses up 4 percent to $738 million. New launches in surgical equipment, intraocular lenses and dry-eye treatment, including Tryptyr, are accelerating the contribution, and further launches of the UnityM microscope and UnityDx diagnostics are planned through late 2026 and 2027. A fresh product cycle in a category Alcon already leads is the kind of multi-year growth driver the price is paying for.
The financial profile supports the premium. Management guided full-year constant-currency sales growth of 5 to 7 percent with core operating margin expansion of 70 to 170 basis points and earnings-per-share growth of 10 to 13 percent, so the company expects the launch cycle to lift both the top line and profitability. Interest coverage near 5.8 times shows the roughly $2.6 billion of net debt is comfortably serviced. A category leader with a fresh product cycle, expanding margins, and double-digit guided earnings growth is exactly the kind of durable compounder whose forward economics the static valuation frames cannot fully credit.
Bear Case
The biggest risks sit outside the income statement, in the regulatory and macro environment that a medical-device and consumer-health company cannot control. Alcon's surgical products are regulated medical devices that require approvals and ongoing compliance, so a delay or setback in clearing the new UNITY platform extensions, the UnityM microscope, UnityDx diagnostics, or the next intraocular lens, would slow the very launch momentum the price assumes. Much of the surgical business also depends on procedure reimbursement, so changes to how cataract and refractive surgery are paid for, in the United States or in major international markets, feed directly into volume and pricing.
Tariffs and currency are a live macro headwind. Alcon manufactures and sells globally and reports in a currency exposed to swings, and management has flagged tariffs as a factor in its margin planning. A medical-device maker with cross-border supply chains faces cost pressure from trade measures that it may struggle to pass on, which can erode the 70 to 170 basis points of margin expansion the guidance promises. The full-year sales guide is set in constant currency precisely because reported results can be pushed around by the exchange rate.
The demand side carries macro sensitivity too, and the valuation leaves no cushion for it. A meaningful share of vision-care and premium-lens revenue is discretionary, tied to consumers choosing premium intraocular lenses or elective refractive surgery, which softens when household budgets tighten. At about 33 times operating income, the price embeds ceiling-level growth for five years, a pace only about 30 percent of comparable companies sustained that long, on top of a single-digit organic growth rate. The static methods, with a blended value near $29, see less than half the current price. If a regulatory delay, a reimbursement change, a tariff hit, or a consumer slowdown trims the launch trajectory, the premium that only the growth frame supports re-rates toward where the asset and earnings methods sit.
Valuation
The price decomposes as a durability premium. The asset, earnings-power and peer-multiple frames all read Alcon as richly valued, and only the forward-growth DCF reaches the $64.67 price, against a blended central value near $29. The static methods sit far below because they price the current operating margin and trailing earnings, which understate a category leader in the middle of a product cycle.
Inverting the price, the market is paying about 33 times operating income, which implies operating growth held near the self-funding ceiling for roughly five years. The recent growth is solid but not explosive, 6 percent sales growth with guided earnings-per-share growth of 10 to 13 percent, so the price is paying for that mid-to-high pace to persist and for margins to keep expanding. The stretch is the duration and the multiple: only about 30 percent of comparable companies sustained ceiling-level growth over a five-year window, and the premium already credits Alcon's leadership and product cycle. The balance sheet is manageable, with net debt at a couple of times operating income and interest coverage near 5.8 times, so leverage is not the constraint. The investment case rests on the UNITY-led surgical cycle and the new vision-care and dry-eye launches delivering durable, margin-accretive growth in a category with favorable demographics. If the launches land and reimbursement and trade conditions stay benign, the compounding justifies the premium; if regulatory, tariff, or demand headwinds slow the cycle, a 33-times multiple supported only by the growth frame has meaningful downside toward the static methods.
Catalysts
The UNITY-led surgical product cycle is the central catalyst. Surgical equipment sales rose 23 percent to $253 million in the first quarter on UNITY momentum, and further launches of the UnityM microscope and UnityDx diagnostics are planned through late 2026 and 2027. The pace of these launches and their pull-through into consumables and intraocular lenses is the key signal that the growth the price assumes is materializing.
The vision-care and dry-eye launches are the second catalyst. Contact lenses grew 4 percent to $738 million, and new products including the Tryptyr dry-eye treatment are accelerating the vision-care contribution. New product uptake and premium intraocular-lens adoption are the items to track, since premium mix supports both growth and margin.
Regulatory, tariff and macro factors are the swing factors. As a regulated medical-device and consumer-health company selling globally, Alcon is exposed to device approvals, procedure reimbursement, tariffs that management has flagged in its margin plans, and currency. Full-year guidance of 5 to 7 percent constant-currency sales growth with 10 to 13 percent earnings-per-share growth is the benchmark, and any revision driven by these external factors is a direct catalyst. Quarterly results remain the main proof point on whether the launch momentum and margin expansion are holding.
Peer Cohorts (Per Segment, With Filing Citations)
Core business (reported)
- COO (The Cooper Companies, Inc.)
- (no filing in the citation store)
- BLCO (Bausch & Lomb Corp)
- (no filing in the citation store)
- STE (STERIS plc)
- (no filing in the citation store)
- MDT (Medtronic plc)
- (no filing in the citation store)
- SYK (STRYKER CORP)
- (no filing in the citation store)
- ZBH (ZIMMER BIOMET HOLDINGS, INC.)
- (no filing in the citation store)
- MMSI (MERIT MEDICAL SYSTEMS INC)
- (no filing in the citation store)
- RMD (ResMed Inc.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.